Business Wire

Intel 471 Releases Report to Help Europe’s Critical Entities Navigate the Network and Information Security Directive (NIS2)

5.11.2024 10:00:00 EET | Business Wire | Press release

Share

Today, Intel 471, a global leader in cyber threat intelligence (CTI) and intelligence-driven solutions, released its new report, NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resiliency.The report offers key insights into how actionable CTI can help organisations navigate Europe’s new cybersecurity regulations, proactively mitigate digital risk, improve cyber resilience, and avoid penalties and fines.

National laws implementing the European Union’s NIS2 Directive (EU) 2022/2555 to lift the cyber resilience of critical infrastructure across Europe went into effect on 18 October 2024. NIS2 has dramatic implications for how important and essential operators of critical services manage cyber risks compared to its predecessor, NIS1, the 2016 Network and Information Systems Directive. It gives regulators wider supervisory powers, introduces higher standards for cyber risk management, mandatory incident reporting and tougher sanctions. If not followed, essential entities face administrative fines of up to €10 million, or 2% of annual global turnover, whichever is higher. This directive is a major shift in cyber risk management and supply chain security for entities operating energy, transport, banking, health, water, digital infrastructure, managed IT services, public administration and many more subsectors.

In this report, Intel 471 outlines how these entities in critical sectors affected by the European Commission’s NIS2 Directive can leverage premier CTI and intelligence-driven threat hunting to proactively mitigate digital threats and meet the directive’s higher risk management and incident reporting requirements. The report provides organizations with best practices to reduce cyber risk, anticipate threats, prioritise remediation of cloud resources and other IT assets, and continuously improve risk management measures to boost resilience and recovery.

“It is the right time to adopt NIS2 given today’s high stakes cybersecurity threat landscape. We’re seeing nation-state and cybercrime activity increasingly overlap, often driven by geopolitical events that create higher risks to all critical sectors in Europe. Defenders are overwhelmed by data and need timely intelligence that helps them focus on emerging threats, adversary tactics, and vulnerabilities that pose the greatest risk to them,” says Michael DeBolt, Chief Intelligence Officer at Intel 471. “Our unmatched human intelligence capability, patented malware emulation and tracking insights, and human-validated automated collection across thousands of threat actor communities help our customers in critical sectors across the globe understand their exposure and proactively mitigate digital risks. We go a step further by providing carefully curated intelligence-driven threat hunting content to rapidly identify and stop advanced threats in their tracks.”

Organisations impacted by NIS2 can utilise Intel 471’s unique CTI capabilities to improve security posture, reduce their attack surface and enhance resilience. “Being prepared with timely and trusted intelligence and threat hunting content that identifies adversarial techniques missed by traditional detection methods is critical for organisations to gain early visibility of emerging threats and proactively respond to cyber incidents. This intelligence-led approach to cyber defense and third party risk is at the heart of NIS2 directive,” says DeBolt.

NIS2’s broader scope than NIS1 dictates that many affected entities are urgently working to mature their CTI programs to better support their NIS2 cyber risk management strategies. The CTI Capability Maturity Model (CTI-CMM) — a free and vendor-neutral, “stakeholder-first” model, sponsored by Intel 471 and 27 other CTI industry expert peers from across the globe, assists organisations in building successful, impactful CTI programs.

For more details and to download the Intel 471 report, please visit: NIS2 Operationalising Cyber Threat Intelligence for Critical Infrastructure Resilience

About Intel 471

Intel 471 empowers enterprises, government agencies, and other organizations to win the cybersecurity war using the real-time insights about adversaries, their relationships, threat patterns, and imminent attacks relevant to their businesses. The company’s platform collects, interprets, structures, and validates human-led, automation-enhanced intelligence, which fuels our external attack surface and advanced behavioral threat hunting solutions. Customers utilize this operationalized intelligence to drive a proactive response to neutralize threats and mitigate risk. Organizations across the globe leverage Intel 471’s world-class intelligence, our trusted practitioner engagement and enablement, and globally dispersed ground expertise as their frontline guardian against the ever-evolving landscape of cyber threats to fight the adversary — and win. Learn more at www.intel471.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241105566758/en/

Contacts

Erica Stuchel
Intel471@w2comm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye